[HTML][HTML] A placebo-controlled trial of bezafibrate in primary biliary cholangitis
C Corpechot, O Chazouillères… - … England Journal of …, 2018 - Mass Medical Soc
Background Patients with primary biliary cholangitis who have an inadequate response to
therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …
therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …
A Placebo-controlled Trial of Bezafibrate in Primary Biliary Cholangitis
C Corpechot, O Chazouillères… - … England Journal of …, 2018 - hal.sorbonne-universite.fr
BACKGROUND Patients with primary biliary cholangitis (PBC) who inadequately respond to
ursodeoxycholic acid (UDCA) therapy are at high risk of disease progression. Fibrates …
ursodeoxycholic acid (UDCA) therapy are at high risk of disease progression. Fibrates …
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
C Corpechot, O Chazouillères… - The New England …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Patients with primary biliary cholangitis who have an inadequate response to
therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …
therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
C Corpechot, O Chazouillères, A Rousseau… - New England Journal …, 2018 - hal.science
Background: Patients with primary biliary cholangitis who have an inadequate response to
therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …
therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
C Corpechot, O Chazouillères… - … England Journal of …, 2018 - u-bourgogne.hal.science
Background: Patients with primary biliary cholangitis who have an inadequate response to
therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …
therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
C Corpechot, O Chazouillères, A Rousseau… - The New England …, 2018 - europepmc.org
BACKGROUND: Patients with primary biliary cholangitis who have an inadequate response
to therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …
to therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
C Corpechot, O Chazouillères, A Rousseau… - New England Journal …, 2018 - cir.nii.ac.jp
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす 大学図書館の本をさがす 日本の …
国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす 大学図書館の本をさがす 日本の …
[引用][C] A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
C Corpechot, O Chazouilleres, A Rousseau… - 2018 - lilloa.univ-lille.fr
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. Toggle navigation
English français Aide | Contact | À Propos | Ouvrir une session Portail HAL | Pages Pro …
English français Aide | Contact | À Propos | Ouvrir une session Portail HAL | Pages Pro …
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
C Corpechot, O Chazouillères… - The New England …, 2018 - mpgjournal.mpg.es
Background Patients with primary biliary cholangitis who have an inadequate response to
therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …
therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
C Corpechot, O Chazouillères, A Rousseau… - New England Journal …, 2018 - hal.science
Background: Patients with primary biliary cholangitis who have an inadequate response to
therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …
therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which …